

Review Article

Vitamin E and supplements offer eye neuroprotection – Myth or reality?

ABSTRACT

Background: Several studies suggested that nutrition might ~~affected~~ have an effect on eye health. Although exposure to nutrients is ubiquitous, on the other hand without it, we generally cannot survive, and an exposure to too high or too low causes health problems. Vitamins are a good example and the ubiquitous exposure to vitamins has led to many epidemiological studies for many diseases, including glaucoma.

The main body of the abstract: Leading causes of vision loss include several eye conditions such as ~~cataracts~~ cataract and glaucoma. The role of nutritional supplementation ~~in preventing~~ to prevent the progression of ocular disease is of great interest to ~~healthcare~~ health-care professionals. It is recognized that the crystalline lens and retina suffer oxidative damage and the most protective agents are anti-oxidant vitamins A, C, and E. The Age-Related Eye Disease Study (AREDS), found that supplementation with vitamins C and E, reduced the risk of developing various ocular diseases. The RDA for vitamin E is 15 mg/day α -tocopherol for both women and men. Vitamin E exists naturally in nuts and seeds, in addition to dark leafy vegetables.

~~In a~~ recent study reported lower plasma levels of vitamin E in POAG subjects.

Conclusion: In conclusion, exposure to nutrients ~~although~~ is ubiquitous, without it, in general, we cannot survive. Conflicting evidence is presented for vitamins A and E in ~~the~~ prevention of ocular disease. ~~Several a number of~~ epidemiological studies showed an increased risk of nuclear or cortical ~~cataracts~~ cataract in people with low blood levels of vitamin E. Furthermore, ~~several a number of~~ studies suggested that nutrition might ~~affected~~ have an effect on the intraocular pressure (IOP) or glaucoma, arbitrated by oxidative stress.

Keywords: glaucoma; vitamin E; antioxidant supplements; crystalline lens; oxidative stress; cataract

Introduction

A recent advance in eye health is the suggestion that vitamins and supplements may be affecting directly the eye or supporting bodily health, on which the eye depends. Vitamins are today often referred to as micronutrients [1]. It is well known that the crystalline lens and retina suffer oxidative damage and the ~~antioxidant~~ anti-oxidant vitamins A, C, and E are protective agents. On the other hand, more or less ~~of~~ 250 million people worldwide suffer from varying degrees of vision loss [2]. Leading causes include several eye conditions such as ~~cataracts~~ cataract, AMD, glaucoma, and diabetic retinopathy. ~~Once All at once~~, recent studies gave controversial reinforcement ~~of~~ the role of nutrition in cataract development [3].

Furthermore, epidemiological studies give contradictory support to the suggestion that nutrition plays a role in the development of ~~cataracts~~ cataract in ~~humans~~ man. In different areas of the world, cataract is more common in people of low socio-economic status, low health care, and low educational level [4, 5]. The role of nutritional supplementation ~~in preventing~~ to prevent the progression of ocular disease is of interest to ~~healthcare~~ health-care professionals and patients.

Those highlighted for possible inclusion were vitamins A, B, C, and E. Conflicting evidence is presented for vitamins A and E in ~~the~~ prevention of ocular disease; these vitamins have significant involvement in the production of rhodopsin and prevention of lipid peroxidation respectively. Improvements in visual function in patients with age-related macular disease have been noted with lutein and zeaxanthin supplementation [6].

The Age-Related Eye Disease Study (AREDS), sponsored by the National Eye Institute in ~~the~~ US, found that supplementation with vitamins C and E, β -carotene, zinc, and copper (Table 1) at levels well above the recommended daily allowances reduced the risk of developing advanced AMD by about 25% [7].

Table 1

Nutrient	Daily dosage	% daily value
Vitamin C (ascorbic acid)	452 mg	754
Vitamin E (DL- α -tocopheryl acetate)	400 IU	1334
Zinc (zinc oxide)	69.6 mg	464
Copper (cupric oxide)	1.6 mg	80
Vitamin A (β -carotene)	28,640 IU (17 mg)	572

Table 1. Nutrition content of the Age-Related Eye Disease Study (AREDS) formulation (after Rasmussen and Johnson, 2013)

Vitamin E

Vitamin E exists naturally as eight distinct fat-soluble compounds of tocopherols and tocotrienols, each subgroup having α , β , γ , and δ subtypes. Nuts and seeds such as sunflower seeds, almonds, and hazelnuts are rich sources of vitamin E, in addition to dark leafy vegetables like spinach and collard greens.

Vitamin E is a fat-soluble antioxidant that prevents the oxidation of fatty acids by reactive oxygen species. The retina is a lipid-rich environment and is bombarded by ultraviolet radiation. In cell culture, vitamin E has been found to enhance the antioxidant ability of lutein to protect retinal pigment epithelial cells from acrolein-induced oxidation [8]. If a molecule of α -tocopherol neutralizes a free radical, then its antioxidant capacity is ~~totally~~ lost. Nevertheless, other antioxidants, like vitamin C, are capable of regenerating the antioxidant ability of α -tocopherol [9].

Vitamin E portrays a family of eight fat-soluble antioxidants: four tocopherols (α -, β -, γ -, and δ -) and four tocotrienols (α -, β -, γ -, and δ -). α -Tocopherol is the form of vitamin E that is actively maintained in the human body and also the major form in blood and tissues [1]. Furthermore, it is the chemical form that ~~assemblesassemble~~ the RDA for vitamin E.

The α -tocopherol shows an antioxidant main function. In contrast, fats are susceptible to destruction by free radicals, through ~~the~~ oxidation. α -Tocopherol attacks free radicals one by one to prevent lipid oxidation. Since the retina contains a high concentration of fatty acids, this seems to be of ~~greater~~ importance [10].

The recommended intake of vitamin E is 22.4 IU, [11,12] whereas the dose used in AREDS2 was 400 IU daily. One ounce of sunflower seeds satisfies the daily RDI, yet 18 times that is needed to reach the doses used in AREDS2.

Other functions of α -tocopherol that would be of benefit to ocular health include effects on the expression and activities of molecules and enzymes in immune and inflammatory cells. Furthermore, α -tocopherol has been shown to inhibit platelet aggregation and to improve vasodilation [13].

The RDA for vitamin E is 15 mg/day α -tocopherol for both women and men (≥ 19 yrs) [13]. The average intake of vitamin E from foods in the US for men and women over 50 years of age is 8.6 and 7.3 mg/day, respectively. Only men and women in the 95th percentile of vitamin E intake or greater have intakes of vitamin E from ~~a~~ diet that ~~meetsmeet~~ the RDA. Vitamin E-rich foods and some suggested serving sizes are shown in Table 2 [11].

Table 2

Food	Serving	Milligrams (α -tocopherol equivalents)
Almonds, slivered	1/4 cup (27 g)	7
Corn oil	1 tb (14 g)	2
Peanuts	1/4 cup (37 g)	3
Peanut butter, smooth	2 tb (32 g)	3
Sunflower seeds	1/4 cup (35 g)	12
Safflower oil	1 tb (14 g)	5
Soybean oil	1 tb (14 g)	1
Wheat-germ oil	1 tb (14 g)	20

Note:

*Edible portion.

Abbreviation: tb, tablespoon.

Table 2. Vitamin E content of foods (after Rasmussen and Johnson, 2013)

Vitamins and glaucoma

Several studies suggested that nutrition might ~~affect~~~~have an effect on~~ eye health. Although exposure to nutrients is ubiquitous, on the other hand without it, we generally cannot survive, and ~~an~~ exposure ~~to~~ too high or too low causes health problems. Vitamins are a good example and the ubiquitous exposure to vitamins has led to many epidemiological studies for many diseases, including glaucoma [22].

Glaucoma is a group of optic neuropathies that involve progressive death of retinal ganglion cells, degeneration of the optic nerve, and ultimately typical alterations, like defects in ~~the~~ visual field [14, 15].

Primary ~~open-angle~~~~open angle~~ glaucoma (POAG) is the most common type and it differs from normal tension glaucoma (NTG) given that in the former, IOP is often elevated [14, 16]. If glaucoma remains uncontrolled, then it forms irreversibly devastating visual consequences [17,18,19]. Current treatment typically involves topical ocular hypotensives as ~~first-line~~~~first line~~ therapy [17].

Age and high intraocular pressure (IOP) have been identified as risk factors for glaucoma ~~development~~~~developing~~. The need to study glaucoma ~~about~~~~in relation to~~ vitamins comes from the observation that glaucoma is the leading cause of irreversible blindness, that almost half of the glaucoma cases are undiagnosed, and that the prevalence is increasing over time [20, 21].

Elevated intraocular pressure (IOP) is considered to be the main risk factor. ~~Despite~~~~In spite of~~ useful therapies by lowering IOP, the disease progress is important for a grade number of patients. Oxidative stress occurs when more reactive oxygen groups are formed ~~than~~~~then~~ the anti-oxidative capacity of the cell can handle. This leads to damage of the aqueous ~~humor~~~~humour~~ outflow system of the eye, ~~and~~ the trabecular meshwork, resulting in an increase in IOP and eventually death of retinal ganglion cells [23, 24].

As a result, alternative strategies aiming mainly to delay RGC degeneration ~~are~~~~is~~ the existing therapeutic scheme for glaucoma [25]. Even so, reducing IOP by hypotonizing drugs or other surgical procedures remains the only available therapy, ~~at present~~~~at the present time~~ [26].

The death of RGCs is the result of several mechanisms including trophic factor deprivation [27], inflammation [28], oxidative stress [29], mitochondrial dysfunction [30], excitotoxicity [31], autophagy dysregulation [32], protein misfolding [33], ischemia, and hypoxia [34]. Each of these methods may support the etiology and progression of the disease, and it is a prospective aim for new neuroprotective, but IOP-independent, management. Significantly, sustained oxidative stress actions should be considered as a key factor [28, 29, 35].

The retina is mainly vulnerable to oxidative stress due to its high consumption of oxygen and proportion of polyunsaturated fatty acids, and its direct exposure to light [36]. This weakness increases with aging, due to the physiological decrease of antioxidant defense mechanisms [36]. High levels of oxidative stress markers have been found in [the](#) aqueous humor of patients with primary [open-angle](#) glaucoma (POAG) and [primary-angle](#) closed glaucoma (PACG) [37, 38].

In a recent study, Zanon-Moreno and colleagues (2013) reported lower plasma levels of vitamin E in POAG subjects [39]. Contrariwise, some studies showed an increase in vitamin E serum levels in glaucoma patients [40]. Two studies on NTG patients showed no difference in vitamin E plasma levels between patients with glaucoma and controls [41, 42] and vice versa, Lopez-Riquelme and colleagues (2015) reported lower vitamin E plasma levels in NTG patients [43].

Nutrition and Cataract

Age-related cataract stands as the major cause of blindness in the world. The prevalence and effects of age-related [cataract](#) are increasing dramatically as the proportion of elderly in our population continues to rise. Diabetic cataracts are caused by an elevation of polyols within the lens of the eye catalyzed by the enzyme aldose reductase. It is estimated that more than 68% of people aged 79 and older have some degree of lens opacification or cataract [44].

[Mechanisms](#) of cataract formation include poor glutathione level add to a not working antioxidant defense system within the eye crystalline lens. Nutrients that may boost glutathione [levels](#) and activity include lipoic acid, vitamins E and C, and selenium [45]. With age, the highly organized crystalline fibers of the transparent crystalline lens are believed to become dehydrated and photo-oxidized, leading to crosslinking and aggregation. Because oxidative damage is supposed to be fundamental in cataract development, many studies have [been](#) required to investigate any protective effect of oral antioxidant supplementation [46].

The results of observational studies suggest that a healthy lifestyle with a diet containing foods rich in antioxidants, particularly lutein and zeaxanthin, as well as n-3 fatty acids, appears possibly beneficial for [cataract](#). Concerning the relation between [cataract](#) and supplements, a few randomized trials were initially designed to evaluate [cataract](#) (2 of these were in China) [47, 48, 49], and 2 other studies evaluated [cataract](#) later in the clinical trials designed for other diseases [50, 51]. A multivitamin-multimineral supplement with a combination of vitamin C, vitamin E, beta-carotene, and zinc (with cupric oxide) may be recommended for AMD but not for [cataract](#) [52].

The cataract analysis of the AREDS trial showed no difference between the intervention groups and placebo on the development or progression of age-related [cataract](#) or loss of visual acuity [47]. Quite the opposite to the Linxian study, the participants in AREDS were predominantly white (96%) and well nourished. The primary outcomes of the study were originally [the](#) progression of lens opacity or cataract surgery and additionally, loss of visual acuity, measured by loss of 15 or more letters in one eye over time. The likelihood of a lens-related event was calculated to be 30% over 5 years in all persons despite the consequences of the intervention [47].

Although the pathogenesis of cortical and [age-related](#) nuclear [cataract](#) are different, oxidative damage has been implicated as an underlying cause of the distinctly different damage phenotypes [53, 54, 55, 56, 57]. Because of this relationship between oxidative stress and cataract formation, it has been proposed that topical application and dietary interventions with antioxidants can be used as therapies to delay or prevent cataract progression. Other nutrients and botanicals, [that](#) may prevent or help prevent cataracts, include panethine, folic acid, melatonin, and bilberry.

[Several](#) epidemiological studies showed an increased risk of nuclear or cortical [cataract](#) in people with low blood levels of vitamin E [58, 59]. The deficit of vitamin E may lead to the formation of toxic peroxides and malondialdehydes due to a generally speeding up of tissue oxidation resulting in lens opacification. Regrettably, an unsophisticated view of supplementing the lens with antioxidants has proven to be ineffective, and in some cases harmful, in delaying cataract progression [53].

The dietary amount of vitamin E supplementation ~~clearly affect~~ **effects** the alteration of protein structure accompanied by the change of glutathione level in the lens. This elevation might effectively protect ~~the~~ lens membrane from lipid peroxidation, which in turn probably reduces the risk of protein oxidation. Accordingly, sufficient antioxidant supplements such as vitamin E may protect lens proteins from oxidative abuse. On the other hand, an excess of vitamin E intake may reduce its inherent advantage of antioxidation.

In summary, there appears to be a general compromise that a diet high in fruit and vegetables containing ~~Vitamins~~ **Vitamin** C, E, ~~and~~ A (Table 3) and multivitamin-mineral supplements may be protective against ~~cataract~~ **cataract**. Data on supplemental antioxidants provided as ~~low-dose~~ **low dose** ~~multivitamins~~ **multivitamin** appear generally positive, while results obtained using single nutrient antioxidants ranged from moderately effective to possibly harmful. Based on current data, a healthy diet, and a multivitamin supplement may offer protection against cataracts. If this is the case, it is important to consider how these nutrients ~~can be able to~~ reach the lens in sufficient quantities to be effective in protecting the lens from oxidative damage.

Table 3

Vitamins	Sources
Vitamin C (L-ascorbic acid)	Citrus fruit, potatoes, broccoli, bell peppers, spinach, strawberries, tomatoes, Brussels sprouts
Vitamin D (cholecalciferol)	Fortified milk and cereals, fatty fish
Vitamin E (tocopherol)	Vegetable Vegetables oils, leafy green vegetables, whole grains, nuts

Table 3. Main sources of vitamins (After Harvard Health Publishing, Harvard Medical School, 2021)

Discussion

Many studies support that vitamin E is an essential antioxidant. Six studies reported a possible association ~~between~~ **of** vitamin E blood levels and glaucoma. One of these studies reported lower plasma levels of vitamin E in the POAG group [43]. One study reported no association [60], and two other studies found increased serum vitamin E levels in glaucoma patients.

For normal tense glaucoma (NTG), one study exhibited lower plasma levels of vitamin E in NTG patients [60], while other studies found no difference in plasma levels of vitamin E between patients with NTG and control groups [60, 61, 62]. Concerning aqueous ~~humor~~ **humour**, lower levels of vitamin E have been reported in patients with POAG and PACG [63]. On the other hand, studies on the dietary intake of vitamin E and its association with OAG announced no significant relation [60].

In conclusion, exposure to nutrients although is ubiquitous, without it, in general, we cannot survive and ~~an~~ exposure ~~too~~ too high or too low amounts causes health problems. Vitamins are a good example and the ubiquitous experience ~~of~~ **vitamin** ~~vitamins~~ action has led to many epidemiological studies for many diseases and glaucoma as well [22]. Furthermore, ~~several a number of~~ studies suggested that nutrition might ~~affect~~ **have an effect on the** intraocular pressure (IOP) or glaucoma, arbitrated by oxidative stress.

Conclusions and Future Strategies

The underlying principle ~~of~~ using nutritional supplementation in glaucoma is persistent by a considerable amount of literature demonstrating that natural ~~compound~~ **compound** enriched with antioxidant, anti-inflammatory, and anti-apoptotic activities are quite successful ~~in preventing~~ **to prevent** RGC death in models of retinal degeneration. On the other hand, the clinical significance of these data is so far to be proven. Indeed, in a considerable quantity of clinical studies, the small number of included patients, the heterogeneity of the study design, and the short follow-up period make it hard to produce the clinical benefit of the treatment. In addition, further vigilance is required in interpreting the results. Nevertheless, although further investigations are desirable to establish their efficacy and safety, nutritional supplementation may stand ~~as~~ **for** an auxiliary in the therapeutic management of glaucoma

The worldwide population is aging, and as a consequence age-related cataracts have grown to an epidemic extent, placing harsh pressures on global and local health systems. Given that the launch of lens cataract is strongly linked with oxidative damage, the use of exogenous antioxidant interventions has been promoted as a technique to keep the progression of lens cataract slow. nevertheless, the majority of these studies are unsuccessful in slowing to slow down cataract progression.

None of the described medical prevention studies demonstrated a convincing success. The mainstream of the results suggests that the protective effect of antioxidant vitamins recognized in earlier case-control and epidemiological studies may have been perplexed by other lifestyle factors [64]. Individuals who are regular users of multivitamin preparations are more likely to be health conscious. Further randomized clinical trials and meta-analysis of data from previous randomized trials will be required to determine whether cataract could be prevented or delayed by using vitamin supplements of any type. Although oxidation and inflammation are highly associated with the etiology of these age-related eye diseases, a recent survey among middle-aged patients showed that well over half of those surveyed were not aware of the important nutrients that play a key role in eye health.

Reference

1. Brown NA, Bron AJ, Harding JJ, Dewar HM. Nutrition supplements and the eye. *Eye (Lond)*. 1998;12 (Pt 1):127-33. doi: 10.1038/eye.1998.21. PMID: 961452
2. Flaxman, S.R.; Bourne, R.R.A.; Resnikoff, S.; Ackland, P.; Braithwaite, T.; Cicinelli, M.V.; Das, A.; Jonas, J.B.; Keeffe, J.; Kempen, J.H.; et al. Global causes of blindness and distance vision impairment 1990–2020: A systematic review and meta-analysis. *Lancet Glob. Health* 2017, 5, e1221–e1234
3. Lawrenson, J. G., & Downie, L. E. (2019). Nutrition and Eye Health. *Nutrients*, 11(9), 2123. <https://doi.org/10.3390/nu11092123>
4. Khan HA, Leibowitz HM, Ganley JP, Kinni MM, Colton T, Nickerson RS, Dawber TR. The Framingham Eye Study. 1. Outline and major prevalence findings. *Am J Ophthalmol* 1977;106:17-32
5. Chatterjee A, Milton Re, Thyle S. Prevalence and aetiology of cataract in Punjab. *Br J Ophthalmol* 1982;66:35-42.
6. Bartlett H, Eperjesi F. An ideal ocular nutritional supplement? *Ophthalmic Physiol Opt*. 2004 Jul;24(4):339-49. doi: 10.1111/j.1475-1313.2004.00218.x. PMID: 15228513.
7. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no 8. *Arch Ophthalmol*. 2001;119:1417–1436. Erratum in *Arch Ophthalmol*. 2008;126:1251.
8. Feng Z, Liu Z, Li X, et al. α -Tocopherol is an effective Phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells. *J Nutr Biochem*. 2010;21:1222-1231
9. Traber MG, Vitamin E. In: *Modern Nutrition in Health and Disease*. Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 396–411
10. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. *Prog Retin Eye Res*. 2005;24:87–138.
11. Rasmussen HM, Johnson EJ. Nutrients for the aging eye. *Clin Interv Aging*. 2013;8:741-8. doi: 10.2147/CIA.S45399. Epub 2013 Jun 19. PMID: 23818772; PMCID: PMC3693724.
12. National Institutes of Health, Office of Dietary Supplements. Vitamin E: fact sheet for health professionals. Available at: <http://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional>. [Accessed November 30, 2013].
13. Traber MG. Does vitamin E decrease heart attack risk? Summary and implications with respect to dietary recommendations. *J Nutr*. 2001;131:395S–397S
14. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. *N Engl J Med*. 2009;360(11):1113-24. Epub 2009/03/13. doi: 10.1056/NEJMra0804630. PubMed PMID: 19279343.
15. Quigley, H.A. Glaucoma. *Lancet* 2011, 377, 1367–1377

16. Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma? *Curr Opin Ophthalmol*. 2008;19(2):85-8. Epub 2008/02/28. doi: 10.1097/ICU.0b013e3282f3919b. PubMed PMID: 18301279.
17. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA*. 2014;311(18):1901-11. Epub 2014/05/16. doi: 10.1001/jama.2014.3192. PubMed PMID: 24825645.
18. Treatment of Primary Open-Angle Glaucoma. *Yale J Biol Med*. 2017;90(1):111-8. Epub 2017/03/31. PubMed PMID:28356898
19. Allingham RR, Damji KF, Shields MB. *Shields textbook of glaucoma*. 6th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. p. 390-9.
20. Wolfs, R.C.; Borger, P.H.; Ramrattan, R.S.; Klaver, C.C.; Hulsman, C.A.; Hofman, A.; Vingerling, J.R.; Hitchings, R.A.; de Jong, P.T. Changing views on open-angle glaucoma: Definitions and prevalences—The Rotterdam Study. *Investig. Ophthalmol. Vis. Sci*. 2000, 41, 3309–3321.
21. Tham, Y.-C.; Li, X.; Wong, T.Y.; Quigley, H.A.; Aung, T.; Cheng, C.-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. *Ophthalmology* 2014, 121, 2081–2090
22. Ramdas, W.D.; Wolfs, R.C.W.; Kieft-de Jong, J.C.; Hofman, A.; de Jong, P.T.V.M.; Vingerling, J.R.; Jansonius, N.M. Nutrient intake and risk of open-angle glaucoma: The Rotterdam Study. *Eur. J. Epidemiol*. 2012, 27, 385–393.
23. Izzotti, A.; Saccà, S.C.; Cartiglia, C.; De Flora, S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. *Am. J. Med*. 2003, 114, 638–646.
24. Izzotti, A.; Bagnis, A.; Saccà, S.C. The role of oxidative stress in glaucoma. *Mutat. Res*. 2006, 612, 105–114.
25. Adornetto A, Rombolà L, Morrone LA, Nucci C, Corasaniti MT, Bagetta G, Russo R. Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma. *Nutrients*. 2020 Oct 16;12(10):3158. doi: 10.3390/nu12103158. PMID: 33081127; PMCID: PMC7602834.
26. Lusthaus, J.; Goldberg, I. Current management of glaucoma. *Med. J. Aust*. 2019, 210, 180–187
27. Chitranshi, N.; Dheer, Y.; Abbasi, M.; You, Y.; Graham, S.L.; Gupta, V. Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects. *Curr. Neuropharmacol*. 2018, 16, 1018–1035
28. Adornetto, A.; Russo, R.; Parisi, V. Neuroinflammation as a target for glaucoma therapy. *Neural Regen. Res*. 2019, 14, 391–39
29. Tang, B.; Li, S.; Cao, W.; Sun, X. The Association of Oxidative Stress Status with Open-Angle Glaucoma and Exfoliation Glaucoma: A Systematic Review and Meta-Analysis. *J. Ophthalmol*. 2019,
30. Kamel, K.; Farrell, M.; O'Brien, C. Mitochondrial dysfunction in ocular disease: Focus on glaucoma. *Mitochondrion* 2017, 35, 44–53
31. Russo, R.; Rotiroli, D.; Tassorelli, C.; Nucci, C.; Bagetta, G.; Bucci, M.G.; Corasaniti, M.T.; Morrone, L.A. Identification of novel pharmacological targets to minimize excitotoxic retinal damage. *Int. Rev. Neurobiol*. 2009, 85, 407–423
32. Russo, R.; Nucci, C.; Corasaniti, M.T.; Bagetta, G.; Morrone, L.A. Autophagy dysregulation and the fate of retinal ganglion cells in glaucomatous optic neuropathy. *Prog. Brain Res*. 2015, 220, 87–105
33. Athanasiou, D.; Aguila, M.; Bevilacqua, D.; Novoselov, S.S.; Parfitt, D.A.; Cheetham, M.E. The cell stress machinery and retinal degeneration. *FEBS Lett*. 2013, 587,
34. Kaur, C.; Foulds, W.S.; Ling, E.A. Hypoxia-ischemia and retinal ganglion cell damage. *Clin. Ophthalmol*. 2008, 2, 879–889
35. Gupta, N.; Yucel, Y.H. Glaucoma as a neurodegenerative disease. *Curr. Opin. Ophthalmol*. 2007, 18, 110–114.
36. Sacca, S.C.; Cutolo, C.A.; Ferrari, D.; Corazza, P.; Traverso, C.E. The Eye, Oxidative Damage and Polyunsaturated Fatty Acids. *Nutrients* 2018, 10, 668.
37. Ghanem, A.A.; Arafa, L.F.; El-Baz, A. Oxidative stress markers in patients with primary open-angle glaucoma. *Curr. Eye Res*. 2010, 35, 295–301
38. Goyal, A.; Srivastava, A.; Sihota, R.; Kaur, J. Evaluation of oxidative stress markers in aqueous humor of primary open angle glaucoma and primary angle closure glaucoma patients. *Curr. Eye Res*. 2014, 39, 823–829.
39. Zanon-Moreno, V.; Asensio-Marquez, E.M.; Ciancotti-Oliver, L.; Garcia-Medina, J.J.; Sanz, P.; Ortega-Azorin, C.; Pinazo-Duran, M.D.; Ordovas, J.M.; Corella, D. Effects of polymorphisms in vitamin E-, vitamin C-, and glutathione peroxidase-related genes on serum biomarkers and associations with glaucoma *Mol. Vis*. 2013, 19, 231–242.[
40. Engin, K.N.; Yemisci, B.; Yigit, U.; Agachan, A.; Coskun, C. Variability of serum oxidative stress biomarkers relative to biochemical data and clinical parameters of glaucoma patients. *Mol. Vis*. 2010, 16, 1260–1271.

41. Yuki, K.; Murat, D.; Kimura, I.; Ohtake, Y.; Tsubota, K. Reduced-serum vitamin C and increased uric acid levels in normal-tension glaucoma. *Graefes Arch. Clin. Exp. Ophthalmol.* 2010, 248, 243–248.
42. Wang, S.Y.; Singh, K.; Lin, S.C. Glaucoma and vitamins A, C, and E supplement intake and serum levels in a population-based sample of the United States. *Eye* 2013, 27, 487–494[37]
43. Lopez-Riquelme, N.; Villalba, C.; Tormo, C.; Belmonte, A.; Fernandez, C.; Torralba, G.; Hernandez, F Endothelin-1 levels and biomarkers of oxidative stress in glaucoma patients. *Int. Ophthalmol.* 2015, 35,527–532.
44. World Health Organization Prevention of blindness and visual impairment
Available at: www.who.int/blindness/en
45. Head KA. Natural therapies for ocular disorders, part two: cataracts and glaucoma. *Altern Med Rev.* 2001 Apr;6(2):141-66. PMID: 11302779.
46. McCusker MM, Durrani K, Payette MJ, Suchecki J. An eye on nutrition: The role of vitamins, essential fatty acids, and antioxidants in age-related macular degeneration, dry eye syndrome, and cataract. *Clin Dermatol.* 2016 Mar-Apr;34(2):276-85. doi: 10.1016/j.clindermatol.2015.11.009. Epub 2015 Nov 22. PMID: 26903189.
47. AREDS Research Group-A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no 9. *Arch Ophthalmol*, 119 (2001), pp. 1439-1452
48. Sperduto RD, Hu TS, Milton RC, et al. The Linxian cataract studies. Two nutrition intervention trials. *Arch Ophthalmol*, 111 (1993), pp. 1246-1253
49. Chylack LT Jr, Brown NP, Bron A, et al. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract *Ophthalmic Epidemiol*, 9 (2002), pp. 49-80
50. Teikari JM, Rautalahti M, Haukka J, et al. Incidence of cataract operations in Finnish male smokers unaffected by alpha-tocopherol or beta carotene supplements *J Epidem Community Health*, 52 (1998), pp. 468-472
51. Christen WG, Manson JE, Glynn RJ, et al. A randomized trial of beta carotene and age-related cataract in US physicians *Arch Ophthalmol*, 120 (2002), pp. 372-378
52. Seddon JM. Multivitamin-multimineral supplements and eye disease: age-related macular degeneration and cataract. *Am J Clin Nutr.* 2007 Jan;85(1):304S-307S. doi: 10.1093/ajcn/85.1.304S. PMID: 17209215.
53. Braakhuis AJ, Donaldson CI, Lim JC, Donaldson PJ. Nutritional Strategies to Prevent Lens Cataract: Current Status and Future Strategies. *Nutrients.* 2019 May 27;11(5):1186. doi: 10.3390/nu11051186. PMID: 31137834; PMCID: PMC6566364.
54. Duncan G, Wormstone IM, Davies PD: The aging human lens: Structure, growth, icalbehaviour. *Br J Ophthalmol*1997;81:818–823.
55. Fecondo JV, Augusteyn RC: Superoxide dismutase, catalase and glutathione peroxidase in the human cataractous lens. *Exp Eye Res* 1983;36:1
56. Hiller R, Sperduto RD, Podgor MJ, et al: Cigarette smoking and the risk of development of lens opacities. The Framingham studies. *Arch Ophthalmol*1997;115:1113–1118.
57. Hirsch RP, Schwartz B: Increased mortality among elderly patients undergoing cataract extraction. *Arch Ophthalmol*1983;101:1034–1037
58. Meyer CH, Sekundo W. Nutritional supplementation to prevent cataract formation. *Dev Ophthalmol.* 2005;38:103-119. doi: 10.1159/000082771. PMID: 15604620.
59. Bates CJ, Chen SJ, MacDonald A, Holden R: Quantitation of vitamin E and a carotenoid pigment in cataractous human lenses, and the effect of a dietary supplement. *Int J VitamNutr Res* 1996; 66:316–21.
60. Wang, S.Y.; Singh, K.; Lin, S.C. Glaucoma and vitamins A, C, and E supplement intake and serum levels in a population-based sample of the United States. *Eye* 2013, 27, 487–494. [CrossRef] [PubMed]
61. Christen WG. Antioxidant vitamins and age-related eye disease. *Proc Assoc Am Physicians.* 1999 Jan-Feb;111(1):16-21. doi: 10.1046/j.1525-1381.1999.09231.x. PMID: 9893153.
62. Seddon JM. Multivitamin-multimineral supplements and eye disease: age-related macular degeneration and cataract. *Am J Clin Nutr.* (2007) Jan;85(1):304S-307S. doi: 10.1093/ajcn/85.1.304S. PMID: 17209215.
63. Goyal, A.; Srivastava, A.; Sihota, R.; Kaur, J. Evaluation of oxidative stress markers in aqueous humor of primary open angle glaucoma and primary angle closure glaucoma patients. *Curr. Eye Res.* (2014), 39, 823–82

64. Klein BEK, Klein R, Lee KE: Incident cataract after a five-year interval and lifestyle factors: The Beaver Dam Eye Study. *Ophthalmic Epidemiol* (1999);6:247–255.

UNDER PEER REVIEW